We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 23, 2020

Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Reduces the Risk of Major Adverse Kidney Events Compared With Other Antihyperglycemics

Diabetes Care


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Care
Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events
Diabetes Care 2020 Sep 10;[EPub Ahead of Print], Y Xie, B Bowe, AK Gibson, JB McGill, Y Yan, G Maddukuri, Z Al-Aly

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading